JW Therapeutics' Relma-Cell Approved in China for R/R Mantle Cell Lymphoma

JW Therapeutics' relma-cel (Carteyva) received NMPA approval for r/r MCL, becoming the first CAR-T therapy for this indication in China. The approval was based on a pivotal trial showing 81.36% best objective response rate and 67.80% best complete response rate among 59 evaluable patients. Relma-cel is also approved for r/r LBCL and FL, and is being explored for autoimmune diseases and SLE.